Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCC NASDAQ:LEXX NASDAQ:LSB NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$6.77+1.7%$8.45$3.08▼$597.60$14.91M0.1572,512 shs139,138 shsLEXXLexaria Bioscience$1.01+1.0%$0.89$0.77▼$3.72$19.56M0.87174,655 shs43,901 shsLSBLakeShore Biopharma$0.83-0.4%$0.91$0.59▼$8.60$17.38M0.5634,958 shs135,365 shsREVBRevelation Biosciences$2.47+6.0%$2.67$2.11▼$60.48$3.96M-0.04136,905 shs12.92 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals+1.65%-11.85%-25.19%+25.72%-97.46%LEXXLexaria Bioscience+1.02%+13.87%+22.95%-0.98%-71.55%LSBLakeShore Biopharma-0.36%-1.40%+3.93%-15.75%-81.75%REVBRevelation Biosciences+6.01%-9.52%+3.78%+2.28%-93.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$6.77+1.7%$8.45$3.08▼$597.60$14.91M0.1572,512 shs139,138 shsLEXXLexaria Bioscience$1.01+1.0%$0.89$0.77▼$3.72$19.56M0.87174,655 shs43,901 shsLSBLakeShore Biopharma$0.83-0.4%$0.91$0.59▼$8.60$17.38M0.5634,958 shs135,365 shsREVBRevelation Biosciences$2.47+6.0%$2.67$2.11▼$60.48$3.96M-0.04136,905 shs12.92 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals+1.65%-11.85%-25.19%+25.72%-97.46%LEXXLexaria Bioscience+1.02%+13.87%+22.95%-0.98%-71.55%LSBLakeShore Biopharma-0.36%-1.40%+3.93%-15.75%-81.75%REVBRevelation Biosciences+6.01%-9.52%+3.78%+2.28%-93.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/ALEXXLexaria Bioscience 3.00Buy$4.00296.04% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest REVB, CYCC, LEXX, and LSB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.007/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $5.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$40K379.12N/AN/A($58.87) per share-0.11LEXXLexaria Bioscience$460K42.95N/AN/A$0.48 per share2.10LSBLakeShore Biopharma$85.67M0.20N/AN/A$3.35 per share0.25REVBRevelation BiosciencesN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-723.64%-145.51%11/10/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%11/25/2025 (Estimated)LSBLakeShore Biopharma-$13.93MN/A0.00∞N/AN/AN/AN/A10/30/2025 (Estimated)REVBRevelation Biosciences-$15.04M-$68.61N/AN/AN/AN/A-240.27%-148.95%11/14/2025 (Estimated)Latest REVB, CYCC, LEXX, and LSB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CYCCCyclacel Pharmaceuticals-$72.00-$0.98+$71.02-$0.98$0.03 millionN/A8/7/2025Q2 2025REVBRevelation Biosciences-$4.46-$7.01-$2.55-$7.01N/AN/A7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A5.775.77LEXXLexaria BioscienceN/A3.903.90LSBLakeShore Biopharma0.051.020.75REVBRevelation BiosciencesN/A3.423.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%LEXXLexaria Bioscience13.06%LSBLakeShore Biopharma52.64%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals51.20%LEXXLexaria Bioscience26.40%LSBLakeShore BiopharmaN/AREVBRevelation Biosciences2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals142.24 million1.09 millionOptionableLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableLSBLakeShore Biopharma77320.77 millionN/AN/AREVBRevelation Biosciences101.70 million1.66 millionNot OptionableREVB, CYCC, LEXX, and LSB HeadlinesRecent News About These CompaniesRevelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical DataSeptember 10 at 7:20 AM | accessnewswire.comAReminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line DataSeptember 9 at 4:55 PM | accessnewswire.comARevelation Biosciences announces topline results from PRIME studySeptember 9 at 11:46 AM | msn.comRevelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical StudySeptember 9 at 8:00 AM | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025August 8, 2025 | businesswire.comRevelation Biosciences Inc. Completes Dosing of Patients in PRIME StudyJuly 16, 2025 | businesswire.comRevelation Biosciences to implement 1-for-3 reverse stock splitJuly 2, 2025 | investing.comRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - MorningstarJuly 2, 2025 | morningstar.comMRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025July 1, 2025 | businesswire.comRevelation Biosciences Inc News (REVB) - Investing.comJune 24, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 31, 2025 | finance.yahoo.comRevelation Biosciences sets terms for $4 million public offeringMay 30, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 29, 2025 | insidermonkey.comRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingMay 29, 2025 | businesswire.comRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingMay 29, 2025 | finance.yahoo.comRevelation Biosciences board member steps down amid new focusMay 25, 2025 | uk.investing.comRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsMay 23, 2025 | businesswire.comREVB On Track and Exploring New MarketsMay 9, 2025 | msn.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, ...May 8, 2025 | gurufocus.comRevelation Biosciences to Develop Gemini for Infection in Severe Burn PatientsApril 29, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREVB, CYCC, LEXX, and LSB Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$6.77 +0.11 (+1.65%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$6.62 -0.15 (-2.29%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Lexaria Bioscience NASDAQ:LEXX$1.01 +0.01 (+1.02%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.89%) As of 09/10/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.LakeShore Biopharma NASDAQ:LSB$0.83 0.00 (-0.36%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$0.85 +0.02 (+1.92%) As of 09/10/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Revelation Biosciences NASDAQ:REVB$2.47 +0.14 (+6.01%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$2.31 -0.17 (-6.68%) As of 05:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
